Details for New Drug Application (NDA): 088127
✉ Email this page to a colleague
NDA 088127 describes HYDROFLUMETHIAZIDE AND RESERPINE, which is a drug marketed by Usl Pharma and Watson Labs and is included in three NDAs. Additional details are available on the HYDROFLUMETHIAZIDE AND RESERPINE profile page.
The generic ingredient in HYDROFLUMETHIAZIDE AND RESERPINE is hydroflumethiazide; reserpine. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide; reserpine profile page.
The generic ingredient in HYDROFLUMETHIAZIDE AND RESERPINE is hydroflumethiazide; reserpine. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide; reserpine profile page.
Summary for 088127
| Tradename: | HYDROFLUMETHIAZIDE AND RESERPINE |
| Applicant: | Watson Labs |
| Ingredient: | hydroflumethiazide; reserpine |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 25MG;0.125MG | ||||
| Approval Date: | Mar 22, 1983 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
